Failed Post-MI Trial Foils Novartis' Higher ASPIRE-ations For Tekturna
This article was originally published in The Pink Sheet Daily
Executive Summary
ACC panelist: Study was not powered for outcomes, but doubling in death rates is still "very disturbing."